Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to ...

The thermochromic labels market is poised for significant growth over the next decade, with a projected compound annual ...

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced new results from the Phase 3 PALISADE study and the open-label extension from the Phase 2 MUIR and SHASTA-2 studies of investigational ...

Q3 2024 Earnings Call Transcript November 18, 2024 Operator: Good afternoon, ladies and gentlemen, and welcome to the NRx ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.

In the Guidance, the FDA posits that poor pharmaceutical label design can contribute to medication errors. To reduce such errors, the FDA seemingly takes a "pro-trade dress" stance by warning ...

In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on Ascendis Pharma (ASND – Research Report), with a price ...

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also ...

IQVIA reported annual sales for the twelve months ending September 2024 of $4.3 billion for the brand and generic market for this product. About Elite Pharmaceuticals, Inc.

TAHO Pharmaceuticals Ltd. announced the dosing of the first subjects in its U.S. Phase III clinical trial for its lead product, TAH3311, an innovative antithrombotic oral dissolving film (ODF). In ...